Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Penumbra (PEN)

Penumbra Reports Third Quarter 2026 Financial Results with Revenue of $410.1 Million

Mixed Impact 3 of 5 earnings

Penumbra reported third quarter 2026 revenue of $410.1 million, representing a 15.6% increase compared to the third quarter of 2025. Net income for the quarter was $42.3 million, down from $45.9 million in the prior year period. Due to the pending acquisition by Boston Scientific Corporation, the company did not provide full-year 2026 financial guidance.

Key points

  • Revenue reached $410.1 million in the third quarter of 2026, up 15.6% year-over-year.
  • Global thrombectomy revenue grew 18.1% to $279.2 million for the quarter ended September 30, 2026.
  • Net income for the third quarter of 2026 was $42.3 million, yielding diluted net income per share of $1.07.
  • Operating expenses totaled $229.6 million, including $7.1 million in acquisition-related expenses tied to the pending Boston Scientific transaction.

The filing

CompanyPenumbra (PEN)
Form8-K, current report
Filed with the SECOct 29, 2026, 4:14 PM ET
Accession number0001321732-26-000042

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Oct 30, 2026, 5:15 PM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.